retatrutide

Retatrutide is an investigational peptide drug developed by Eli Lilly for the treatment of obesity and related metabolic conditions. It is a once-weekly, subcutaneous injection that acts as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide 1 (GLP-1) receptor, and glucagon receptor. By simultaneously activating these three receptors, retatrutide targets multiple metabolic pathways to promote weight loss, improve glycemic control, and enhance lipid metabolism. In phase 2 clinical trials, retatrutide demonstrated substantial reductions in body weight—up to 24.2% after 48 weeks—and improvements in cardiometabolic markers such as non-HDL cholesterol and triglycerides. The most common side effects are gastrointestinal in nature during dose escalation. Retatrutide is currently being studied for obesity/overweight management, type 2 diabetes mellitus, fatty liver disease (including NASH), and cardiovascular risk reduction[1][4][5][7][9][10].

Other names

triple G